Clinical outcomes and safety profile of Tenecteplase in wake‐up stroke
Acta Neurologica Scandinavica2020Vol. 142(5), pp. 475–479
Citations Over TimeTop 21% of 2020 papers
Hassan Khan Ahmed, Nicola Logallo, Lars Thomassen, Vojtěch Novotný, Sara Maria Mathisen, Martin Kurz
Abstract
In WUPS patients treated in NOR-TEST, there was no difference in clinical outcomes at 90 days and no ICH events or deaths were observed in either alteplase- or tenecteplase-treated patients. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT01949948.
Related Papers
- → Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials(2016)84 cited
- → Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: Insights from the TETRIS registry(2022)39 cited
- → Abstract TMP24: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)(2018)4 cited
- → Intravenous thrombolysis by tenecteplase: Experience of the neurology department of Chu Hassan II Fez, Morocco(2019)
- → OUTCOME OF INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE IN ACUTE ISCHEMIC STROKE.(2022)